Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts

December 22, 2011

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ — Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today the Company will relocate its corporate headquarters to Cambridge, MA from Laguna Niguel, CA. The move is integral to Inspiration’s plan to accommodate its anticipated future staffing and facility needs as the Company transitions to product commercialization.

Inspiration’s new location at One Kendall Square is ideally located within the greater Boston area’s technology and life sciences cluster. The new address is:

Inspiration Biopharmaceuticals
One Kendall Square
Cambridge, MA 02139

John P. Butler, Chief Executive Officer of Inspiration, commented, “The Boston metro area has always been a center for growth and innovation in the biopharmaceutical industry. As we move toward the launch of Inspiration’s first products, including IB1001, our recombinant factor IX product for hemophilia B, it is the perfect location to establish our corporate office. We expect the close proximity to some of the leading academic and research institutions will help attract top talent as we continue to build a world-class company focused on improving the life of individuals with hemophilia.”

In October 2011, Inspiration named John P. Butler Chief Executive Officer. Mr. Butler joined Inspiration from Cambridge-based Genzyme Corporation, where he most recently served as President of the company’s rare genetic diseases business.

One Kendall Square is in the heart of Cambridge’s life-sciences community. Since its inception, this address has served as headquarters for many early-stage to mid-tier companies, including a number that have gone on to develop blockbuster drugs and employ thousands of workers in Greater Boston. The office and research park is situated on nine acres.

About Inspiration Biopharmaceuticals
Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care to safe and effective recombinant therapies and advance innovation for people living with these conditions. Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two preclinical programs.

Inspiration’s lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment of individuals with congenital hemophilia A who have developed inhibitors against human FVIII and for individuals with acquired hemophilia. Inspiration recently submitted its first marketing application for IB1001 in Europe, with a subsequent regulatory filing planned in the U.S. Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration’s senior management team has broad experience and expertise in hemophilia product development, biologics manufacturing and the successful commercialization of products to treat both hemophilia as well as chronic orphan diseases.

In addition, in January 2010, Inspiration entered into a strategic partnership with the Ipsen Group (EURONEXT: IPN; ADR: IPSEY), leveraging the combined expertise and resources of the two companies, to develop a broad portfolio of hemophilia products. As announced in late August 2011, Ipsen and Inspiration extended their partnership to create a hemophilia business unit structure that will act as the exclusive sales organization for all hemophilia products commercialized under the Inspiration brand in Europe. For further information on Inspiration, please visit http://www.inspirationbio.com.

    Contacts:
    Media                       Company
    Justin Jackson              Gordon H. Busenbark
    Michelle Szwarcberg         Senior Vice President, Chief Financial Officer
    Burns McClellan             Email: gbusenbark@inspirationbio.com
    Tel: +1-212-213-0006
    Email: jjackson@burnsmc.com
    mszwarcberg@burnsmc.com

SOURCE Inspiration Biopharmaceuticals, Inc.


Source: PR Newswire